237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes.

Authors :: Pantel, K.
Lindbjerg Andersen, C.
Schuuring, E.
Malats, N.
Heitzer, E.
Vat, L.
Kiernan, E.
Chin, E.
Barrett, J.C.
Kapp, J.R.
Thomas, M.
Gerling, M.
Reck, M.
Löhr, M.
Hofman, P.
Hiltermann, J.T.J.N.
Alix-Panabières, C.
Smit, D.J.
Bolisetty, M.
Karasarides, M.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS276-S277. 2p.
Publication Year :: 2023

Subjects :: *CIRCULATING tumor DNA
*COMBINED modality therapy
*CONSORTIA
*BIOPSY
*LIQUIDS

Full Text Access

Tools